Patent ID: 9512213
Filing Date: 2016-12-06
CPC Classification: A61K,C07K,C12N,G01N

Claim Text:
1. A method for treating a disease in a vertebrate subject with an immunotherapeutic product comprising: isolating from a vertebrate subject exposed to at least one second antigen, a B lymphocyte cell expressing at least one endogenous secreted immunoglobulin reactive to the at least one second antigen; introducing into the isolated B lymphocyte cell at least one exogenous membrane immunoglobulin reactive to at least one first antigen to produce a recombinant B lymphocyte cell; selecting the recombinant B lymphocyte cell expressing the membrane immunoglobulin reactive to the at least one first antigen and expressing the at least one endogenous secreted immunoglobulin reactive to the at least one second antigen; and administering a therapeutically effective amount of said recombinant B lymphocyte cell to one or more vertebrate subjects afflicted with disease.